Vinay K. Puduvalli, M.D.

Peer-Reviewed Articles

1. Alnahhas I, Rayi A, Ong S, Giglio P, Puduvalli V. Management of gliomas in patients with Lynch syndrome. Neuro Oncol 23(1):167-168, 2021. PMID: 33059358.
2. Puduvalli VK. Demystifying demethylator sensitivity in gliomas: role for TERT and DNMT1. Neuro Oncol 23(1):7-8, 2021. PMID: 33264399.
3. Alnahhas I, Rayi A, Thomas D, Ong S, Giglio P, Puduvalli V. False-positive 1p/19q Testing Results in Gliomas: Clinical and Research Consequences. Am J Clin Oncol 43(11):802-805, 2020. PMID: 32889892.
4. Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert MR. A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro Oncol 22(10):1505-1515, 2020. PMID: 32166308.
5. Venere M, Zadeh G, Puduvalli V, Haynes C. SNO 25th anniversary history series: Ancillary and satellite meetings of the Society for Neuro-Oncology. Neuro Oncol 22(9):1231-1232, 2020. PMID: 32991721.
6. Puduvalli V, Venere M, Haynes C, Zadeh G. SNO 25th anniversary history series: The SNO Annual Meeting - A nexus for science, collaboration and community. Neuro Oncol 22(8):1053-1055, 2020. PMID: 32804242.
7. Gatson NTN, Bross SP, Odia Y, Mongelluzzo GJ, Hu Y, Lockard L, Manikowski JJ, Mahadevan A, Kazmi SAJ, Lacroix M, Conger AR, Vadakara J, Nayak L, Chi TL, Mehta MP, Puduvalli VK. Early imaging marker of progressing glioblastoma: a window of opportunity. J Neurooncol 148(3):629-640, 2020. e-Pub 2020. PMID: 32602020.
8. Venere M, Zadeh G, Puduvalli V, Haynes C. Celebrating SNO's official journal, Neuro-Oncology. Neuro Oncol 22(5):585-586, 2020. PMID: 32415306.
9. Venere M, Zadeh G, Puduvalli V, Haynes C. The Society for Neuro-Oncology: 20/20 vision for the future. Neuro Oncol 22(4):435-436, 2020. PMID: 32095809.
10. Freeman T, Legasto CS, Schickli MA, McLaughlin EM, Giglio P, Puduvalli V, Gonzalez J. High-dose methotrexate-based regimens with or without vincristine for the treatment of primary central nervous system lymphoma. Neurooncol Adv 2(1):vdaa077, 2020. e-Pub 2020. PMID: 32715297.
11. Alnahhas I, Alsawas M, Rayi A, Palmer JD, Raval R, Ong S, Giglio P, Murad MH, Puduvalli V. Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. Neurooncol Adv 2(1):vdaa082, 2020. e-Pub 2020. PMID: 33150334.
12. Wang JL, Barth RF, Cavaliere R, Puduvalli VK, Giglio P, Lonser RR, Elder JB. Phase I trial of intracerebral convection-enhanced delivery of carboplatin for treatment of recurrent high-grade gliomas. PLoS One 15(12):e0244383, 2020. e-Pub 2020. PMID: 33373402.
13. Lai TH, Mitchell S, Wu PJ, Orwick S, Liu C, Ravikrishnan J, Woyach J, Mims A, Plunkett W, Puduvalli VK, Byrd JC, Lapalombella R, Sampath D. HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics. Leuk Lymphoma 60(9):2308-2311, 2019. e-Pub 2019. PMID: 30773117.
14. Dornbos D, Elder JB, Otero JJ, Baiocchi RA, Slone HW, Puduvalli VK, Giglio P. Spinal Cord Toxicity from Intrathecal Chemotherapy: A Case with Clinicopathologic Correlation. World Neurosurg 128:381-384, 2019. e-Pub 2019. PMID: 31128312.
15. Carpenter CD, Alnahhas I, Gonzalez J, Giglio P, Puduvalli VK. Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target. Expert Rev Neurother 19(7):663-677, 2019. e-Pub 2019. PMID: 31106606.
16. Mitchell SR, Larkin K, Grieselhuber NR, Lai TH, Cannon M, Orwick S, Sharma P, Asemelash Y, Zhang P, Goettl VM, Beaver L, Mims A, Puduvalli VK, Blachly JS, Lehman A, Harrington B, Henderson S, Breitbach JT, Williams KE, Dong S, Baloglu E, Senapedis W, Kirschner K, Sampath D, Lapalombella R, Byrd JC. Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. Blood Adv 3(3):242-255, 2019. PMID: 30692102.
17. Makary MS, Awan U, Puduvalli VK, Slone HW. Stroke-Like Migraine Attacks after Radiation Therapy Syndrome: Clinical and Imaging Characteristics. J Clin Imaging Sci 9:5, 2019. e-Pub 2019. PMID: 31448156.
18. Nabar GM, Mahajan KD, Calhoun MA, Duong AD, Souva MS, Xu J, Czeisler C, Puduvalli VK, Otero JJ, Wyslouzil BE, Winter JO. Micelle-templated, poly(lactic-co-glycolic acid) nanoparticles for hydrophobic drug delivery. Int J Nanomedicine 13:351-366, 2018. e-Pub 2018. PMID: 29391794.
19. Puduvalli VK, Hoang N. Chemotherapy of High-Grade Astrocytomas in Adults. Prog Neurol Surg 31:116-144, 2018. e-Pub 2018. PMID: 29393181.
20. Goceri E, Goksel B, Elder JB, Puduvalli VK, Otero JJ, Gurcan MN. Quantitative validation of anti-PTBP1 antibody for diagnostic neuropathology use: Image analysis approach. Int J Numer Method Biomed Eng 33(11), 2017. e-Pub 2017. PMID: 28024117.
21. Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, Engh A. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. J Natl Compr Canc Netw 15(11):1331-1345, 2017. PMID: 29118226.
22. Canella A, Welker AM, Yoo JY, Xu J, Abas FS, Kesanakurti D, Nagarajan P, Beattie CE, Sulman EP, Liu J, Gumin J, Lang FF, Gurcan MN, Kaur B, Sampath D, Puduvalli VK. Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas. Clin Cancer Res 23(20):6215-6226, 2017. e-Pub 2017. PMID: 28679777.
23. Kesanakurti D, Maddirela D, Banasavadi-Siddegowda YK, Lai TH, Qamri Z, Jacob NK, Sampath D, Mohanam S, Kaur B, Puduvalli VK. A novel interaction of PAK4 with PPARγ to regulate Nox1 and radiation-induced epithelial-to-mesenchymal transition in glioma. Oncogene 36(37):5309-5320, 2017. e-Pub 2017. PMID: 28534509.
24. Williams MM, Mashaly H, Puduvalli VK, Jin M, Mendel E. Immunoglobulin G4-related disease mimicking an epidural spinal cord tumor: case report. J Neurosurg Spine 26(1):76-80, 2017. e-Pub 2016. PMID: 27517527.
25. Puduvalli VK, Chaudhary R, McClugage SG, Markert J. Beyond Alkylating Agents for Gliomas: Quo Vadimus?. Am Soc Clin Oncol Educ Book 37:175-186, 2017. PMID: 28561663.
26. Wang JL, Hong CS, Otero J, Puduvalli VK, Elder JB. Genetic Characterization of a Multifocal Ganglioglioma Originating Within the Spinal Cord. World Neurosurg 96:608.e1-608.e4, 2016. e-Pub 2016. PMID: 27671879.
27. LeBlanc AK, Mazcko C, Brown DE, Koehler JW, Miller AD, Miller CR, Bentley RT, Packer RA, Breen M, Boudreau CE, Levine JM, Simpson RM, Halsey C, Kisseberth W, Rossmeisl JH, Dickinson PJ, Fan TM, Corps K, Aldape K, Puduvalli V, Pluhar GE, Gilbert MR. Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients. Neuro Oncol 18(9):1209-18, 2016. e-Pub 2016. PMID: 27179361.
28. Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WKA, de Groot JF. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. J Neurooncol 129(3):487-494, 2016. e-Pub 2016. PMID: 27406589.
29. Puduvalli VK. Vaccine Therapies Against Gliomas: Prime Time Yet?. Oncology (Williston Park) 30(3):222-3, 2016. PMID: 26984214.
30. Hamza MA, Kamiya-Matsuoka C, Liu D, Yuan Y, Puduvalli VK. Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms. J Neurooncol 126(3):527-33, 2016. e-Pub 2015. PMID: 26566652.
31. Welker AM, Jaros BD, Puduvalli VK, Imitola J, Kaur B, Beattie CE. Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity. Dis Model Mech 9(2):199-210, 2016. e-Pub 2015. PMID: 26659251.
32. Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yuan Y, Liu D, Rademaker A, Yung WK, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont-Lukats IW, De Groot J, Aldape K, Gilbert MR, Brain Tumor Trials Collaborative. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. J Neurooncol 126(1):185-192, 2016. PMID: 26476729.
33. Walbert T, Glantz M, Schultz L, Puduvalli VK. Impact of provider level, training and gender on the utilization of palliative care and hospice in neuro-oncology: a North-American survey. J Neurooncol 126(2):337-45, 2016. e-Pub 2015. PMID: 26518539.
34. Usubalieva A, Pierson CR, Kavran CA, Huntoon K, Kryvenko ON, Mayer TG, Zhao W, Rock J, Ammirati M, Puduvalli VK, Lehman NL. Primary Meningeal Pleomorphic Xanthoastrocytoma With Anaplastic Features: A Report of 2 Cases, One With BRAF(V600E) Mutation and Clinical Response to the BRAF Inhibitor Dabrafenib. J Neuropathol Exp Neurol 74(10):960-9, 2015. PMID: 26352988.
35. Fauzi MFA, Gokozan HN, Elder B, Puduvalli VK, Pierson CR, Otero JJ, Gurcan MN. A multi-resolution textural approach to diagnostic neuropathology reporting. J Neurooncol 124(3):393-402, 2015. e-Pub 2015. PMID: 26255070.
36. Walbert T, Puduvalli VK, Taphoorn MJB, Taylor AR, Jalali R. International patterns of palliative care in neuro-oncology: a survey of physician members of the Asian Society for Neuro-Oncology, the European Association of Neuro-Oncology, and the Society for Neuro-Oncology. Neurooncol Pract 2(2):62-69, 2015. e-Pub 2015. PMID: 31386064.
37. Melguizo-Gavilanes I, Bruner JM, Guha-Thakurta N, Hess KR, Puduvalli VK. Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?. J Neurooncol 123(1):141-50, 2015. e-Pub 2015. PMID: 25894594.
38. Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR, MD Anderson Community Clinical Oncology Program, Brain Tumor Trials Collaborative. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol 17(2):266-73, 2015. e-Pub 2014. PMID: 25239666.
39. Theeler BJ, Ellezam B, Melguizo-Gavilanes I, de Groot JF, Mahajan A, Aldape KD, Bruner JM, Puduvalli VK. Adult brainstem gliomas: Correlation of clinical and molecular features. J Neurol Sci 353(1-2):92-7, 2015. e-Pub 2015. PMID: 25934342.
40. Thorne AH, Meisen WH, Russell L, Yoo JY, Bolyard CM, Lathia JD, Rich J, Puduvalli VK, Mao H, Yu J, Caligiuri MA, Tridandapani S, Kaur B. Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance. Mol Ther 22(9):1678-87, 2014. e-Pub 2014. PMID: 24895995.
41. Hamza MA, Mandel JJ, Conrad CA, Gilbert MR, Yung WK, Puduvalli VK, DeGroot JF. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma. J Neurooncol 119(1):135-40, 2014. e-Pub 2014. PMID: 24803001.
42. Theeler BJ, Ellezam B, Sadighi ZS, Mehta V, Tran MD, Adesina AM, Bruner JM, Puduvalli VK. Adult pilocytic astrocytomas: clinical features and molecular analysis. Neuro Oncol 16(6):841-7, 2014. e-Pub 2014. PMID: 24470550.
43. Anderson MD, Hamza MA, Hess KR, Puduvalli VK. Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. Neuro Oncol 16(6):823-8, 2014. e-Pub 2014. PMID: 24596117.
44. Barney CL, Brown AP, Grosshans DR, McAleer MF, de Groot JF, Puduvalli V, Tucker SL, Crawford CN, Gilbert MR, Brown PD, Mahajan A. Technique, outcomes, and acute toxicities in adults treated with proton beam craniospinal irradiation. Neuro Oncol 16(2):303-9, 2014. e-Pub 2013. PMID: 24311638.
45. Gopisetty G, Xu J, Sampath D, Colman H, Puduvalli VK. Epigenetic regulation of CD133/PROM1 expression in glioma stem cells by SP 1/Myc and Promoter Methylation. Oncogene 32(26):3119-29, 2013. e-Pub 2012. PMID: 22945648.
46. Fakhreddine MH, Mahajan A, Penas-Prado M, Weinberg J, McCutcheon IE, Puduvalli V, Brown PD. Treatment, prognostic factors, and outcomes in spinal cord astrocytomas. Neuro Oncol 15(4):406-12, 2013. e-Pub 2013. PMID: 23322747.
47. Dziurzynski K, Blas-Boria D, Suki D, Cahill DP, Prabhu SS, Puduvalli V, Levine N. Butterfly glioblastomas: A retrospective review and qualitative assessment of outcomes. J Neurooncol 109(3):555-63, 2012. e-Pub 2012. PMID: 22806339.
48. Ellezam B, Theeler BJ, Walbert T, Mammoser AG, Horbinski C, Kleinschmidt-DeMasters BK, Perry A, Puduvalli V, Fuller GN, Bruner JM, Aldape KD. Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas. Acta Neuropathol 124(3):449-51, 2012. e-Pub 2012. PMID: 22772980.
49. Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern R, Xu J, Desideri S, Ye X, Ames M, Espinoza-Delgado I, Prados MD, Wen PY. Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res. e-Pub 2012. PMID: 22923449.
50. Giglio P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, Kang SL, Ictech SE, Liu V, Colman H, Conrad CA, Loghin M, de Groot J, Yung WK, Puduvalli VK. Phase II Trial of Irinotecan and Thalidomide in Adults with Recurrent Anaplastic Glioma. Cancer 118(14):3599-606, 2012. e-Pub 2011. PMID: 22086614.
51. Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Lada P, Prados M, Goldin J, Wen PY, Cloughesy T. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol 108(3):491-8, 2012. e-Pub 2012. PMID: 22426926.
52. Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG, Keating MJ. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 119(5):1162-72, 2012. e-Pub 2011. PMID: 22096249.
53. Xu J, Sampath D, Lang FF, Prabhu S, Rao G, Fuller GN, Liu Y, Puduvalli VK. Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures. J Neurooncol 105(2):241-251, 2011. e-Pub 2011. PMID: 21598070.
54. Wu J, Langford LA, Schellingerhout D, Guha-Thakurta N, Tummala S, Weinberg JS, Puduvalli VK. Progressive multifocal leukoencephalopathy in a patient with glioblastoma. J Neurooncol 103(3):791-6, 2011. e-Pub 2010. PMID: 21120583.
55. Ong SS, Bruner J, Schellingerhout D, Puduvalli VK. Papillary endothelial hyperplasia presenting as recurrent malignant glioma. J Neurooncol 102(3):491-8, 2011. e-Pub 2010. PMID: 20740304.
56. Walbert T, Gilbert MR, Groves MD, Puduvalli VK, Yung WK, Conrad CA, Bobustuc GC, Colman H, Hsu SH, Bekele BN, Qiao W, Levin VA. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma. J Neurooncol 102(2):273-80, 2011. e-Pub 2010. PMID: 20652724.
57. Liu Y, Lang F, Xie X, Prabhu S, Xu J, Sampath D, Aldape K, Fuller G, Puduvalli VK. Efficacy of Adenovirally Expressed Soluble TRAIL in Human Glioma Organotypic Slice Culture and Glioma Xenografts. Cell Death Dis 2:e121, 2011. e-Pub 2011. PMID: 21368892.
58. Gilbert MR, Gonzalez J, Hunter K, Hess K, Giglio P, Chang E, Puduvalli V, Groves MD, Colman H, Conrad C, Levin V, Woo S, Mahajan A, de Groot J, Yung WK. A Phase I Factorial Design Study of Dose-Dense Temozolomide Alone and in Combination with Thalidomide, Isotretinoin, and/or Celecoxib as Post-chemoradiation Adjuvant Therapy for Newly Diagnosed Glioblastoma. Neuro Oncol 12(11):1167-1172, 2010. e-Pub 2010. PMID: 20729242.
59. Deorukhkar A, Shentu S, Park HC, Diagaradjane P, Puduvalli V, Aggarwal B, Guha S, Krishnan S. Inhibition of radiation-induced DNA repair and prosurvival pathways contributes to vorinostat-mediated radiosensitization of pancreatic cancer cells. Pancreas 39(8):1277-83, 2010. PMID: 20531243.
60. Cortez MA, Nicoloso MS, Shimizu M, Rossi S, Gopisetty G, Molina JR, Carlotti C, Tirapelli D, Neder L, Brassesco MS, Scrideli CA, Tone LG, Georgescu MM, Zhang W, Puduvalli V, Calin GA. miR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma. Genes Chromosomes Cancer 49(11):981-90, 2010. PMID: 20665731.
61. Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA. Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma. J Clin Oncol 28(7):1168-74, 2010. e-Pub 2010. PMID: 20124186.
62. Groves MD, Hess KR, Puduvalli V, Colman H, Conrad CA, Gilbert MR, Weinberg J, Cristofanilli M, Yung WKA, Liu TJ. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 94(2):229-34, 2009. e-Pub 2009. PMID: 19267183.
63. Groves MD, Puduvalli VK, Gilbert MR, Levin VA, Conrad CA, Liu VH, Hunter K, Meyers C, Hess KR, Alfred Yung WK. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. Br J Cancer 101(4):615-20, 2009. PMID: 19672263.
64. Sampath D, Calin GA, Puduvalli VK, Gopisetty G, Taccioli C, Liu CG, Ewald B, Liu C, Keating MJ, Plunkett W. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 113(16):3744-53, 2009. e-Pub 2008. PMID: 19096009.
65. de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol 90(1):89-97, 2008. e-Pub 2008. PMID: 18581057.
66. Puduvalli VK, Giglio P, Groves MD, Hess K, Gilbert MR, Mahankali S, Jackson E, Levin V, Conrad CA, Hsu S, Colman H, deGroot J, Ritterhouse MG, Ictech S, Yung WKA. Phase II trial of Irinotecan and Thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol 10(2):216-222, 2008. e-Pub 2008. PMID: 18314417.
67. Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK.. A Multicenter Phase II Trial of Intrathecal Topotecan in Patients with Meningeal Malignancies. Neuro Oncol 10(2):208-215, 2008. e-Pub 2008. PMID: 18316473.
68. Kyritsis AP, Puduvalli VK, Levin VA. Chemotherapy as first line treatment for oligodendroglioma. J Neurooncol 86(3):361-362, 2008. e-Pub 2007. PMID: 17710374.
69. Kyritsis AP, Tachmazoglou F. Rao JS, Puduvalli VK. Temozolomide and resistant glioma cells. J Neurosurg 108(1):197, 2008. PMID: 18173334.
70. Kyritsis AP, Rao JS, Puduvalli VK. Radio-responsive TRAIL gene therapy for malignant gliomas. Cancer Gene Ther 14(12):1002, 2007. e-Pub 2007. PMID: 17704752.
71. Kyritis AP, Tachmazoglou F, Rao JS, Puduvalli VK. Bortezomib sensitizes human astrocytoma cells to tumor necrosis factor related apoptosis-inducing ligand induced apoptosis. Clin Cancer Res 13(21):6540-6541, 2007. PMID: 17975168.
72. Kyritsis AP, Rao JS, Puduvalli VK. Prognostic factors in multifocal gliomas: in regard to Showalter et al. Int J Radiat Oncol Biol Phys 69:820-824, 2007.
73. Kyritsis AP, Rao JS, Puduvalli VK. Prognostic factors in multifocal gliomas: in regard to Showalter et al. (Int J Radiat Oncol Biol Phys 2007;69:820-824). Int J Radiat Oncol Biol Phys 69(4):1335; author reply 1335, 2007. PMID: 17967325.
74. Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, Deangelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 81(3):271-7, 2007. e-Pub 2006. PMID: 17031561.
75. Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaeckle K, Liu V, Hess KR, Aldape KD, Levin VA. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol 80(1):83-90, 2006. e-Pub 2006. PMID: 16639492.
76. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12(16):4899-907, 2006. PMID: 16914578.
77. Levin VA, Giglio P, Puduvalli VK, Jochec J, Groves MD, Yung WK, Hess K. Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. J Neurooncol 78(1):85-90, 2006. e-Pub 2005. PMID: 16391896.
78. Puduvalli VK, Li JT, Chen L, McCutcheon IE. Induction of apoptosis in primary meningioma cultures by fenretinide. Cancer Res 65:1547-53, 2005. PMID: 15735044.
79. Puduvalli VK, Sampath D, Bruner JM, Nangia J, Xu R, Kyritsis AP. TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 10(1):233-43, 2005. PMID: 15711939.
80. Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol 22:4282-9, 2004. PMID: 15514370.
81. Tran HT, Blumenschein GR, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 54(4):308-314, 2004. e-Pub 2004. PMID: 15184994.
82. Wang LE, Bondy ML, Shen H, El-Zein R, Aldape K, Cao Y, Puduvalli V, Levin VA, Yung WK, Wei Q. Polymorphisms of DNA repair genes and risk of glioma. Cancer Res 64:5560-3, 2004. PMID: 15313891.
83. Puduvalli VK, Hashmi M, McAllister LD, Levin VA, Hess KR, Prados M, Jaeckle KA, Yung WK, Buys SS, Bruner JM, Townsend JJ, Davis R, Sawaya R, Kyritsis AP. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology 65(3):259-66, 2003. PMID: 14657600.
84. Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP, Puduvalli VK. Brain metastasis from prostate carcinoma: The M. D. Anderson Cancer Center experience. Cancer 98:363-8, 2003. PMID: 12872358.
85. Herbst RS, Madden TL, Tran HT, Blumenschein GR, Jr, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA, Jr, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol 20:4440-7, 2002. PMID: 12431966.
86. Lang FF, Gilbert MR, Puduvalli VK, Weinberg J, Levin VA, Yung WK, Sawaya R, Fuller GN, Conrad CA. Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. Neuro-oncol 4:268-77, 2002. PMID: 12356357.
87. Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20:1383-8, 2002. PMID: 11870183.
88. Puduvalli VK. Brain metastases: biology and the role of the brain microenvironment. Curr Oncol Rep 3:467-75, 2001. PMID: 11595114.
89. Puduvalli VK, Kyritsis AP, Hess KR, Bondy ML, Fuller GN, Kouraklis GP, Levin VA, Bruner JM. Patterns of expression of Rb and p16 in astrocytic gliomas, and correlation with survival. Int J Oncol 17(5):963-9, 2000. PMID: 11029499.
90. Puduvalli VK, Sawaya R. Antiangiogenesis -- therapeutic strategies and clinical implications for brain tumors. J Neurooncol 50:189-200, 2000. PMID: 11245279.
91. Saitoh Y, Goto T, Puduvalli VK, Murakami M, Kochi M, Levin VA, Kyritsis AP, Ushio Y. Induction of apoptosis by N-(4-hydroxyphenyl)retinamide in glioma cells. Int J Oncol 15:499-504, 1999. PMID: 10427131.
92. Puduvalli VK, Saito Y, Xu R, Kouraklis GP, Levin VA, Kyritsis AP. Fenretinide activates caspases and induces apoptosis in gliomas. Clin Cancer Res 5:2230-5, 1999. PMID: 10473110.
93. Puduvalli VK, Yung AW. New frontiers in therapy of malignant gliomas. Forum (Genova) 8:261-9, 1998. PMID: 9755291.
94. Fueyo J, Gomez-Manzano C, Puduvalli VK, Martin-Duque P, Perez-Soler R, Levin VA, Yung WK, Kyritsis AP. Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy. Int J Oncol 12:665-9, 1998. PMID: 9472109.
95. Puduvalli VK, Sella A, Austin SG, Forman AD. Carpal tunnel syndrome associated with interleukin-2 therapy. Cancer 77:1189-92, 1996. PMID: 8635142.
96. Ong S, Wei Q, Bekele N, Guha-Thakurta G, Puduvalli V. Heterogeneity of response to bevacizumab in multifocal and multicentric glioblastomas. JCO.

Manuals, Teaching Aids, Other Teaching Publications

1. Puduvalli V. Patient Information Manual. UT MD Anderson Cancer Center: Houston, Texas, 2002.

Abstracts

1. Puduvalli VK, Xu J, Sampath D, Liu Y.. Vorinostat (Suberoylanilide Hydroxamic Acid) induces G2-M arrest and apoptosis in glioma cells. Neuro-Oncology, Proceedings from 11th Annual Meeting of the Society for Neuro-Oncology (SNO), Orlando, FL, November 16-19, 2006 8(4):416, 2006.
2. Penas-Prado M., Puduvalli VK. Medulloblastoma in adults: A retrospective review of the M. D. Anderson Cancer Center (MDACC) experience. Neuro-Oncology, Proceedings from 11th Annual Meeting of the Society for Neuro-Oncology (SNO), Orlando, FL, November 16-19, 2006 8(4):448, 2006.
3. Gilbert MR, Gonzalez J, Hunter K, Hess K, Chang E, Puduvalli VK, Groves M, Colman H, Conrad C, Levin V, Woo S, Mahajan A, Hsu S, de Groot J, Yung WKA.. A Phase I study for a factorial design of dose-dense Temozolomide (TMZ) alone and in Combination with permutations of Thalidomide (THAL), Isotretinoin (CRA) and/or Celecoxib (CEL) as post-chemoradiation adjuvant therapy for newly diagnosed glioblastoma (GBM). Neuro-Oncology, Proceedings from 11th Annual Meeting of the Society for Neuro-Oncology (SNO), Orlando, FL, November 16-19, 2006 8(4):442, 2006.
4. Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson E, Levin VA, Conrad CA, Hsu S, Colman H, Ritterhouse M, Ichtech S, Yung WKA.. Phase II trial of Irinotecan and Thalidomide in adult patients with recurrent glioblastoma multiforme. Neuro-Oncology, Proceedings from 11th Annual Meeting of the Society for Neuro-Oncology (SNO), Orlando, FL, November 16-19, 2006 8(4):450, 2006.
5. Gilbert MR, Gaupp P, Liu V, Conrad C, Colman H, Groves M, Puduvalli V, Levin V, Hsu S, Horowitz J, Yung W.. A phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), Ionafarnib (Sarazar, SCH66336) in recurrent glioblastoma. J of Clinical Oncology, Proceedings from 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Atlanta, GA, June 2-6, 2006 24(18S):1556, 2006.
6. Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Hsu S, Colman H, Conrad C, Levin VA, Yung, WKA.. Phase II study of the combination of thalidomide and irinotecan in patients with recurrent anaplastic gliomas not on enzyme inducing anticonvulsants. J of Clinical Oncology, Proceedings from . 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO), Atlanta, GA, June 2-6, 2006 24(18S):1564, 2006.
7. Wong FC, Groves M, Papadopulos N, Conrad C, Meyers C, Fonnegra A, Puduvalli V, Hsu S and Kim EE.. A phase I study using I-131 Nal to treat leptomeningeal metastasis via lumbar puncture. J Nuc Med 47(Supp 1):80P, 2006.
8. Krishnan S, Shentu S, Schwartz DL, Puduvalli VK.. Suberoylanilide hydroxamic acid (SAHA) sensitizes pancreatic cancer cells to radiation therapy. Proceedings from poster presentation at the 52nd Annual Meeting of the Radiation Research Society, Denver CO, Oct 17, 2005, 2005.
9. Groves MG, Puduvalli V, Gilbert, M, Conrad CA, Liu V, Hess K, Yung WKA, Levin VA.. Matrix metalloproteinase inhibitor-induced joint-related toxicity predicts prolonged progression-free survival in recurrent high-grade glioma trials. Proceedings of the Society of Neuro-Oncology/6th Annual Meeting of the European Association of Neuro-Oncology/2nd Quadrennial Meeting of the World Federation of Neuro-Oncology, 2005.
10. Groves MD, Puduvalli V, Gilbert MR, Conrad CA, Hsu S, Colman H, Hess K, Levin VA, Yung, WKA.. A phase II study of temozolomide plus pegylated interferon alfa-2b for recurrent anaplastic glioma and glioblastoma multiforme. J of Clinical Oncology, Proceedings from 41st Annual Meeting of the American Society of Clinical Oncology (ASCO), Orlando, FL, May 13-17, 2005 23(16S):1519, 2005.
11. Puduvalli VK, Giglio P, Groves MD, Hess K, Jackson E, Mahankali S, Gilbert MR, Levin VA, Conrad CA, Hsu S, Colman H, Subramaniam H, Hunter G and WKA Yung.. Phase II trial of Thalidomide in combination with Irinotecan in adults with recurrent glioblastomas. J of Clinical Oncology, Proceedings from 41st Annual Meeting of the American Society of Clinical Oncology (ASCO), Orlando, FL, May 13-17, 2005 23(16S):1524, 2005.
12. Puduvalli VK, Xu J, Sampath, D.. Suberoylanilide hydroxamic acid (SAHA) induces G2 arrest and apoptosis in gliomas. Proceedings of the 96th Annual meeting of the American Association for Cancer Research (AACR) 46:1808, 2005.
13. Puduvalli VK, Xu J, Liu X, Sampath D.. In vitro activity of SAHA, an HDAC inhibitor, against gliomas. Proceedings of the American Association for Cancer Research (AACR) Special Conference on Chromatin, Chromosomes, and Cancer Epigenetics, Waikoloa Hawaii, November 10 – November 14, 2004, 2004.
14. Gilbert MR, Hess K, Gaupp P, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, DePorre P, Yung WKA. A Phase I study of Temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), Tipifarnib (Zarnestra, R115777) in recurrent glioblastoma: A dose and schedule intensive regimen. Neuro-Oncology, Proceedings from 9th Annual Meeting of the Society for Neuro-Oncology 6(4):375, 2004.
15. Groves MD, Liu TJ, Hess KR, Forman AD, Hsu SH, Gilbert MR, Colman H, Puduvalli VK, Conrad CA, Yung, WKA. Cerebrospinal fluid VEGF levels as a biomarker of neoplastic meningitis. Neuro-Oncology, Proceedings from 9th Annual Meeting of the Society for Neuro-Oncology 6(4):352, 2004.
16. Wen PY, Yung WKA, Lamborn K, Peng, B, Dahia P, Abrey, L, Raiser J, Cloughesy T, Fink K, Gilbert M, Chang, S, Junck L, Schiff D, Lieberman F, Fine H, Mehra M, Robins JI, DeAngelis LM, Hess, Groves M, Puduvalli VK, Levin V, Conrad C, Kuhn J, Maher E, Hayes M, Silberman S, Letvak L, Capdeville R, Kaplan R, Murgo A, Stiles C, Prados MD.. Phase I/II study of Imatinib Mesylate (ST1571) for patients with recurrent malignant gliomas (NABTC 98-08). Neuro-Oncology, Proceedings from 9th Annual Meeting of the Society for Neuro-Oncology 6(4):385, 2004.
17. Raizer JJ, Abrey LE, Wen P, Cloughesy T, Robins IA, Fine HA, Lieberman F, Puduvalli VK, Fink KL, Prados M.. A phase II trial of erlotinib (OSI-774) in patients with recurrent malignant gliomas (MG) not on EIAEDs. Journal of Clinical Oncology, Proceedings from 2004 ASCO Annual Meeting, New Orleans, LA, June 6, 2004 22 (14S):#1502, 2004.
18. Groves MD, Baumgartner KE, Conrad CA, Chamberlain M, Hsu S, Glantz M, Gilbert M, Forman A, Puduvalli V, Colman H, Yung WKA.. A phase II study of intrathecal topotecan in patients with meningeal malignancies. Neurology, Proceedings from the 56th Annual Meeting of the American Academy of Neurology, San Francisco, CA, April 24 - May 1, 2004 62 (Suppl 5):A475, 2004.
19. Puduvalli VK, Sampath D, Liu Y. In vitro activity of the HDAC inhibitor Suberoylanilide hydroxamic acid (SAHA) against gliomas. Proceedings from 95th Annual Meeting of the American Association for Cancer Research (AACR):Abstract #4171, 2004.
20. Puduvalli VK, Sampath D, Liu Y. In vitro activity of the HDAC inhibitor Suberoylanilide hydroxamic acid (SAHA) against gliomas. Proceedings from the 95th Annual Meeting of the American Association for Cancer Research (AACR), abstract #4171, Orlando, Florida, March 27-31, 2004, 2004.
21. Wang LE, Bondy ML, Shen H, El-Zein R, Aldape K, Puduvalli V, Levin VA, Yung WKA, Wei Q.. Polymorphism of DNA double-strand break repair gene XRCC7 and risk of glioma. Neuro-Oncology - Proceedings from Annual Meeting of the Society for Neuro-Oncology, Keystone, CO, 5(4):315, 2003.
22. Gilbert MR, Hess K, Liu V, Groves M, Puduvalli V, Conrad C, Levin V, Yung WKA.. Combination therapy using radiation and cytostatic agents: A cautionary tale. Neuro-Oncology, Proceedings from 8th Annual Meeting of the Society for Neuro-Oncology, Keystone, CO, 5(4):343, 2003.
23. Groves M, Conrad C, Chamberlain M, Hsu S, Gilbert M, Forman A, Levin V, Puduvalli V, Colman H, Yung WKA.. A phase II study of intrathecal topotecan in patients with meningeal malignancies. Neuro-Oncology, Proceedings 8th Annual Meeting of the Society for Neuro-Oncology, Keystone, CO, 5(4):350, 2003.
24. Puduvalli, V, Yung WKA, Prados M, Kuhn J, Hess K, Groves, M, Levin V, Chang S, Zwiebel J, Cloughesy T.. Phase II trial of fenretinide in patients with recurrent malignant gliomas – A North American Brain Tumor Consortium study. Meeting Proceedings of the American Society of Clinical Oncology, 39th Annual Meeting, Chicago, IL 22:#419, 2003.
25. Tremont-Lukats IW, Puduvalli V. Diagnostic performance of 201 thallium single photon emission computed tomography (201T spect) and MRS in patients with previously irradiated gliomas with new enhancing lesions on MRI. Neuro-Oncology, Proceedings from Society for Neuro-Oncology Seventh Annual Meeting, San Diego CA, 4(4):363, 2002.
26. Tremont-Lukats IW, Puduvalli V, Groves MD. Can Spect, MRS, and dynamic MRI help clinicians to distinguish tumor recurrence from treatment effect: A comparison using post-test probabilities. Neuro-Oncology, Proceedings from the Fifth Congress of the European Association for Neuro-Oncology, Florence Italy 4, Supplement 1:Abstract #316, 2002.
27. VA Levin, Phuphanich S, Glantz MJ, Mason WP, Groves MD, Recht LD, Shaffrey M, Puduvalli V, Roeck B, Zhang MH, Collier MA. Randomized phase II study of temozolomide (TMZ) with and without the matrix metalloprotease (MMP) inhibitor prinomastat in patients with glioblastoma multiforme (GBM) following best surgery and radiation therapy. Proceedings from American Society of Clinical Oncology Annual meeting, 2002.
28. Puduvalli V, Ridgway L, XU R, Nangia J, Bruner JM, Kyritsis AP. Modulation of apoptotic and survival pathways in gliomas by TRAIL. Proceedings of the American Association for Cancer Research 43:Abstract #3488, 2002.
29. Puduvalli V, McCutcheon IE, Chen L, Li JT.. Induction of apoptosis in primary meningioma cells by fenretinide. Proceedings of the American Association for Cancer Research 43:Abstract #4685, 2002.
30. Puduvalli VK. Poster Presentation “Identification of a novel protein that associates with DR5– the receptor for TRAIL”. Proceedings from the American Academy for Cancer, 2001.
31. Joseph JR, Waguespack SG, Mahajan A, Puduvalli V, Fuller GN, McCutcheon IE. Pituitary carcinoma:experience from a single institution. American Association of Neurological Surgeons, Miami FL, April 14-18, 2012.

Book Chapters

1. Puduvalli V. Epigenetics of Gliomas. In: Glioma Cell Biology. Springer, 2013.
2. Puduvalli, VK. Aberrations of the epigenome in gliomas: Novel targets for therapy. In: Glioblastoma: Molecular mechanisms of pathogenesis and current therapeutic strategies. Springer -Verlag: New York, NY, 185-202, 2010.
3. Grunfeld J, Puduvalli V. Role of Brain Microenvironment in Brain Metastases. In: Integration/Interaction of Oncologic Growth, (Cancer Growth and Progression). 1. Springer: The Netherlands, 127-148, 2005.
4. Puduvalli V, Armstrong T. Management of patients with brain metastasis. In: Palliative Care Consultations - Primary and Metastatic Brain Tumours. Oxford University Press: USA, 2004.
5. Puduvalli V. Inhibition of angiogenesis as a therapeutic strategy against brain tumors. In: Angiogenesis in Brain Tumors (Cancer Treatment and Research). Springer: USA, 307-336, 2004.
6. Puduvalli V. Neurogenetic syndromes associated with nervous system neoplasms. In: Atlas of Cancer. Lippincott Williams & Wilkins: USA, , 607 – 616, 2002.